TOP TEN perturbations for 38880_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38880_at
Selected probe(set): 213394_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38880_at (213394_at) across 6674 perturbations tested by GENEVESTIGATOR:
precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample
Relative Expression (log2-ratio):2.5822458Number of Samples:36 / 74
Experimental | precursor-B-ALL study 1 (t(1;19)(q23,q13)) |
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
c-ALL/pre-B-ALL study 1 / normal bone marrow sample
Relative Expression (log2-ratio):2.4442635Number of Samples:232 / 74
Experimental | c-ALL/pre-B-ALL study 1 |
Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample
Relative Expression (log2-ratio):2.4223146Number of Samples:70 / 74
Experimental | precursor-B-ALL study 1 (t(11q23)) |
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11)) / normal bone marrow sample
Relative Expression (log2-ratio):2.3754177Number of Samples:121 / 74
Experimental | c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11)) |
Bone marrow samples of patients with c-ALL/pre-B-ALL (t(9;22)(q34,q11)/BCR-ABL). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-2.1195793Number of Samples:5 / 6
Experimental | atopic dermatitis study 21 (lesional; whole skin) |
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal skin tissue |
Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-2.1140032Number of Samples:5 / 6
Experimental | atopic dermatitis study 21 (non-lesional; whole skin) |
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal skin tissue |
Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
TNF-ɑ; IL-1b; IL-6; PGE2 study 1 / control antibody treated immature dendritic cell sample
Relative Expression (log2-ratio):1.9669371Number of Samples:4 / 5
Experimental | TNF-ɑ; IL-1b; IL-6; PGE2 study 1 |
Immature dendritic cells (DCs) treated with inflammatory cytokine cocktail (10 ng/ml IL-1b, 1,000 U/ml IL-6, 10 ng/ml TNF-ɑ, 1μg/ml prostaglandin E2) for 24 h. | |
Control | control antibody treated immature dendritic cell sample |
Immature dendritic cells (DCs) treated with isotype control antibody (10 - 20μg/ml mouse IgG1 isotype) for 24 h. |
stem cell differentiation study 59 (iDRG; 12d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):1.9080553Number of Samples:4 / 4
Experimental | stem cell differentiation study 59 (iDRG; 12d) |
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper. | |
Control | normal embryonic stem cell sample (WA09) |
Undifferentiated WA09 embryonic stem cell samples. |
precursor-B-ALL study 2 (E2A-PBX1) / precursor-B-ALL study 2 (TEL-AML1)
Relative Expression (log2-ratio):1.8790302Number of Samples:2 / 21
Experimental | precursor-B-ALL study 2 (E2A-PBX1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
Control | precursor-B-ALL study 2 (TEL-AML1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG). |
precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)
Relative Expression (log2-ratio):-1.8230085Number of Samples:15 / 5
Experimental | precursor-B-ALL study 3 (TEL-AML1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
Control | precursor-B-ALL study 3 (MLL-rearranged) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |